Pays: Canada
Langue: anglais
Source: Health Canada
RITONAVIR
ABBVIE CORPORATION
J05AE03
RITONAVIR
100MG
CAPSULE
RITONAVIR 100MG
ORAL
120
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0128780001; AHFS:
CANCELLED POST MARKET
2014-11-25
_ _ _NORVIR_ _®_ _, NORVIR_ _®_ _ SEC Product Monograph _ _Page 1 of 78 _ _Date of Revision: June 13, 2014 and Control No. 173634 _ PRODUCT MONOGRAPH PR NORVIR ® Ritonavir film-coated tablets (100 mg) PR NORVIR ® Ritonavir oral solution (80 mg/mL) PR NORVIR ® SEC Ritonavir soft elastic capsules (100 mg) Human Immunodeficiency Virus (HIV) Protease Inhibitor AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway July 21, 2014 St-Laurent, Qc H4S 1Z1 Submission Control No: 173634 _ _ _NORVIR_ _®_ _, NORVIR_ _®_ _ SEC Product Monograph _ _Page 2 of 78 _ _Date of Revision: June 13, 2014 and Control No. 173634 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................6 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................23 DOSAGE AND ADMINISTRATION ..............................................................................34 OVERDOSAGE ................................................................................................................37 ACTION AND CLINICAL PHARMACOLOGY ............................................................37 STORAGE AND STABILITY ..........................................................................................42 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................43 PART II: SCIENTIFIC INFORMATION ............................................................. Lire le document complet